These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 16285267)
1. Study of cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma. Céruse P; Rabilloud M; Charrié A; Dubreuil C; Disant F Ann Otol Rhinol Laryngol; 2005 Oct; 114(10):768-76. PubMed ID: 16285267 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours. Banal A; Hacene K; Berthelot-Ruff E; Mahé E; Fontana X; Pichon MF Tumour Biol; 2001; 22(1):27-35. PubMed ID: 11054024 [TBL] [Abstract][Full Text] [Related]
3. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897 [TBL] [Abstract][Full Text] [Related]
4. [Study of Cyfra 21-1 as a new tumor marker for the diagnosis of epidermoid carcinoma of the head and neck]. González Sánchez E; López-Ríos Velasco J; Calvo Boizas E; García-Talavera Fernández JR; Martín Ro-dríguez M; Muñoz Herrera A; Del Cañizo Alvarez A Acta Otorrinolaringol Esp; 1999 Mar; 50(2):85-9. PubMed ID: 10217679 [TBL] [Abstract][Full Text] [Related]
5. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma. Al-Shagahin H; Alkotyfan K; Müller HH; Sesterhenn AM; Werner JA Anticancer Res; 2009 Aug; 29(8):3421-5. PubMed ID: 19661367 [TBL] [Abstract][Full Text] [Related]
6. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374 [TBL] [Abstract][Full Text] [Related]
7. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778 [TBL] [Abstract][Full Text] [Related]
8. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Yen TC; Lin WY; Kao CH; Cheng KY; Wang SJ Clin Otolaryngol Allied Sci; 1998 Feb; 23(1):82-6. PubMed ID: 9563673 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy. Gauthé M; Richard-Molard M; Rigault E; Buecher B; Mariani P; Bellet D; Cacheux W; Lièvre A BMC Cancer; 2018 Apr; 18(1):417. PubMed ID: 29653564 [TBL] [Abstract][Full Text] [Related]
10. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck. Kuropkat C; Lippert BM; Werner JA Oncology; 2002; 63(3):280-5. PubMed ID: 12381908 [TBL] [Abstract][Full Text] [Related]
11. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246 [TBL] [Abstract][Full Text] [Related]
12. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547 [TBL] [Abstract][Full Text] [Related]
13. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Park SY; Lee JG; Kim J; Park Y; Lee SK; Bae MK; Lee CY; Kim DJ; Chung KY Lung Cancer; 2013 Feb; 79(2):156-60. PubMed ID: 23206831 [TBL] [Abstract][Full Text] [Related]
14. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Ogawa T; Tsurusako Y; Kimura N; Nishioka S; Akagi H; Nishizaki K; Nishioka K; Rutka J Acta Otolaryngol Suppl; 1999; 540():72-6. PubMed ID: 10445084 [TBL] [Abstract][Full Text] [Related]
15. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742 [TBL] [Abstract][Full Text] [Related]
16. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706 [TBL] [Abstract][Full Text] [Related]
17. Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma. Kimura Y; Fujieda S; Takabayashi T; Tanaka T; Sugimoto C; Saito H Cancer Lett; 2000 Jul; 155(2):163-8. PubMed ID: 10822131 [TBL] [Abstract][Full Text] [Related]
18. Analysis of preoperative serum levels of MMP1, -2, and -9 in patients with site-specific head and neck squamous cell cancer. Kalfert D; Ludvikova M; Topolcan O; Windrichova J; Malirova E; Pesta M; Celakovsky P Anticancer Res; 2014 Dec; 34(12):7431-41. PubMed ID: 25503184 [TBL] [Abstract][Full Text] [Related]
19. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719 [TBL] [Abstract][Full Text] [Related]
20. Early diagnosis of radiotherapy failure for patients with head and neck cancer: the role of biochemical markers. Mrochem-Kwarciak J; Rutkowski T; Wygoda A; Deja R; Hajduk A; Składowski K Tumori; 2018 Aug; 104(4):273-279. PubMed ID: 28604997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]